These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. James ND; Sydes MR; Mason MD; Clarke NW; Anderson J; Dearnaley DP; Dwyer J; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann GN; Bertelli G; Birtle AJ; O'Sullivan JM; Protheroe A; Sheehan D; Srihari N; Parmar MK; Lancet Oncol; 2012 May; 13(5):549-58. PubMed ID: 22452894 [TBL] [Abstract][Full Text] [Related]
5. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Vale CL; Burdett S; Rydzewska LHM; Albiges L; Clarke NW; Fisher D; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Sweeney CJ; Sydes MR; Tombal B; Tierney JF; Lancet Oncol; 2016 Feb; 17(2):243-256. PubMed ID: 26718929 [TBL] [Abstract][Full Text] [Related]
6. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis. Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430 [TBL] [Abstract][Full Text] [Related]
13. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Sydes MR; Parmar MK; Mason MD; Clarke NW; Amos C; Anderson J; de Bono J; Dearnaley DP; Dwyer J; Green C; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann G; James ND Trials; 2012 Sep; 13():168. PubMed ID: 22978443 [TBL] [Abstract][Full Text] [Related]
14. STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply. James ND; Sydes MR; Clarke NW; Mason MD; Parmar MK Lancet; 2016 Jul; 388(10041):235-6. PubMed ID: 27479566 [No Abstract] [Full Text] [Related]
15. Docetaxel with or without zoledronic acid for castration-resistant prostate cancer. Pan Y; Jin H; Chen W; Yu Z; Ye T; Zheng Y; Weng Z; Wang F Int Urol Nephrol; 2014 Dec; 46(12):2319-26. PubMed ID: 25224665 [TBL] [Abstract][Full Text] [Related]
16. Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. Sternberg CN Eur Urol; 2016 Jun; 69(6):1155-6. PubMed ID: 27302137 [No Abstract] [Full Text] [Related]
17. Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. Taneja SS J Urol; 2016 Oct; 196(4):1124-5. PubMed ID: 27628795 [No Abstract] [Full Text] [Related]
19. Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis. Zhang P; Wen F; Fu P; Yang Y; Li Q Tumori; 2017 Jul; 103(4):380-386. PubMed ID: 28009424 [TBL] [Abstract][Full Text] [Related]
20. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]